Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 5/2021

01-10-2021 | Hepatocellular Carcinoma | Clinical trial methodologies

Identification of CDC20 as an immune infiltration-correlated prognostic biomarker in hepatocellular carcinoma

Authors: Chen Xiong, Zhihuai Wang, Guifu Wang, Chi Zhang, Shengjie Jin, Guoqing Jiang, Dousheng Bai

Published in: Investigational New Drugs | Issue 5/2021

Login to get access

Summary

Hepatocellular carcinoma (HCC) is a malignancy with a poor prognosis. E3 ubiquitin-protein ligases play essential roles in HCC, such as regulating progression, migration, and metastasis. We aimed to explore a hub E3 ubiquitin-protein ligase gene and verify its association with prognosis and immune cell infiltration in HCC. Cell division cycle 20 (CDC20) was identified as a hub E3 ubiquitin-protein ligase in HCC by determining the intersecting genes in a protein-protein interaction (PPI) network of differentially expressed genes (DEGs) using HCC data from the International Cancer Genome Consortium (ICGC) and the gene list of 919 E3 ubiquitin-protein ligases. DEGs and their correlations with clinicopathological features were explored in The Cancer Genome Atlas (TCGA), ICGC, and Gene Expression Omnibus (GEO) databases via the Wilcoxon signed-rank test. The prognostic value of CDC20 was illustrated by Kaplan-Meier (K-M) curves and Cox regression analyses. Subsequently, the correlation between CDC20 and immune infiltration was demonstrated via the Tumor Immune Estimation Resource (TIMER) and Gene Expression Profiling Interactive Analysis (GEPIA). CDC20 expression was significantly higher in HCC than in normal tissues (all P < 0.05). High CDC20 expression predicted a poor prognosis and might be an independent risk factor in HCC (P < 0.05). Additionally, CDC20 was correlated with the immune infiltration of CD8 + T cells, T cells (general), monocytes, and exhausted T cells. This study reveals the potential prognostic value of CDC20 in HCC and demonstrates that CDC20 may be an immune-associated therapeutic target in HCC because of its correlation with immune infiltration.
Literature
1.
2.
Llovet JM, Montal R, Sia D, Finn RS (2018) Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol 15(10):599–616CrossRefPubMed
3.
Li R, Wang Y, Zhang X, Feng M, Ma J, Li J, Yang X, Fang F, Xia Q, Zhang Z et al (2019) Exosome-mediated secretion of LOXL4 promotes hepatocellular carcinoma cell invasion and metastasis. Mol Cancer 18(1):18PubMedPubMedCentralCrossRef
4.
Li W, Wang H, Ma Z, Zhang J, Ou-Yang W, Qi Y, Liu J (2019) Multi-omics analysis of microenvironment characteristics and immune escape mechanisms of hepatocellular carcinoma. Front Oncol 9:1019PubMedPubMedCentralCrossRef
5.
Wang D, Ma L, Wang B, Liu J, Wei W (2017) E3 ubiquitin ligases in cancer and implications for therapies. Cancer Metastasis Rev 36(4):683–702PubMedCrossRef
6.
Liu J, Peng Y, Zhang J, Long J, Liu J, Wei W (2020) Targeting SCF E3 ligases for cancer therapies. Adv Exp Med Biol 1217:123–146PubMedCrossRef
7.
Yang L, Chen J, Huang X, Zhang E, He J, Cai Z (2018) Novel Insights Into E3 ubiquitin ligase in cancer chemoresistance. Am J Med Sci 355(4):368–376PubMedCrossRef
8.
Kurebayashi Y, Ojima H, Tsujikawa H, Kubota N, Maehara J, Abe Y, Kitago M, Shinoda M, Kitagawa Y, Sakamoto M (2018) Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification. Hepatology 68(3):1025–1041PubMedCrossRef
9.
10.
11.
Patel SP, Kurzrock R (2015) PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 14(4):847–856PubMedCrossRef
12.
Zhou J, Xu Y, Lin S, Guo Y, Deng W, Zhang Y, Guo A, Xue Y (2018) iUUCD 2.0: an update with rich annotations for ubiquitin and ubiquitin-like conjugations. Nucleic Acids Res 46(D1):D447-Dd453PubMedCrossRef
13.
Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, Bernabé RR, Bhan MK, Calvo F, Eerola I, Gerhard DS et al (2010) International network of cancer genome projects. Nature 464(7291):993–998PubMedCrossRef
14.
Tomczak K, Czerwińska P, Wiznerowicz M (2015) The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp Oncol (Poznan Poland) 19(1a):A68–A77
15.
Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M et al (2013) NCBI GEO: archive for functional genomics data sets–update. Nucleic Acids Res 41(Database issue):D991–D995PubMed
16.
Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, Santos A, Doncheva NT, Roth A, Bork P et al (2017) The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res 45(D1):D362-Dd368PubMedCrossRef
17.
Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13(11):2498–2504PubMedPubMedCentralCrossRef
18.
Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, Li B, Liu XS (2017) TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res 77(21):e108–e110PubMedPubMedCentralCrossRef
19.
Yoshihara K, Shahmoradgoli M, Martínez E, Vegesna R, Kim H, Torres-Garcia W, Treviño V, Shen H, Laird PW, Levine DA et al (2013) Inferring tumor purity and stromal and immune cell admixture from expression data. Nat Commun 4:2612CrossRefPubMed
20.
Aran D, Sirota M, Butte AJ (2015) Systematic pan-cancer analysis of tumor purity. Nat Commun 6:8971PubMedCrossRef
21.
Danaher P, Warren S, Dennis L, D’Amico L, White A, Disis ML, Geller MA, Odunsi K, Beechem J, Fling SP (2017) Gene expression markers of tumor infiltrating leukocytes. J Immunother Cancer 5:18PubMedPubMedCentralCrossRef
22.
Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA (2018) Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol (Clifton NJ) 1711:243–259CrossRef
23.
Siemers NO, Holloway JL, Chang H, Chasalow SD, Ross-MacDonald PB, Voliva CF, Szustakowski JD (2017)Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors. PLoS One 12(7):e0179726PubMedPubMedCentralCrossRef
24.
25.
Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z (2017) GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res 45(W1):W98-Ww102PubMedPubMedCentralCrossRef
26.
Pan JH, Zhou H, Cooper L, Huang JL, Zhu SB, Zhao XX, Ding H, Pan YL, Rong L (2019) LAYN is a prognostic biomarker and correlated with immune infiltrates in gastric and colon cancers. Front Immunol 10:6PubMedPubMedCentralCrossRef
27.
Soave DF, Miguel MP, Tomé FD, de Menezes LB, Nagib PR, Celes MR (2016) The fate of the tumor in the hands of microenvironment: role of TAMs and mTOR pathway. Mediat Inflamm 2016:8910520CrossRef
28.
Kreileder M, Barrett I, Bendtsen C, Brennan D, Kolch W (2021) Signaling dynamics regulating crosstalks between T-Cell activation and immune checkpoints. Trends Cell Biol 31(3):224–235PubMedCrossRef
29.
Zhu L, Qin C, Li T, Ma X, Qiu Y, Lin Y, Ma D, Qin Z, Sun C, Shen X et al (2020) The E3 ubiquitin ligase TRIM7 suppressed hepatocellular carcinoma progression by directly targeting Src protein. Cell Death Differ 27(6):1819–1831PubMedCrossRef
30.
He H, Wu Z, Li S, Chen K, Wang D, Zou H, Chen H, Li Y, Liu Z, Qu C (2020) TRAF7 enhances ubiquitin-degradation of KLF4 to promote hepatocellular carcinoma progression. Cancer Lett 469:380–389PubMedCrossRef
31.
Shao G, Wang R, Sun A, Wei J, Peng K, Dai Q, Yang W, Lin Q (2018) The E3 ubiquitin ligase NEDD4 mediates cell migration signaling of EGFR in lung cancer cells. Mol Cancer 17(1):24PubMedCrossRefPubMedCentral
32.
Dong LQ, Peng LH, Ma LJ, Liu DB, Zhang S, Luo SZ, Rao JH, Zhu HW, Yang SX, Xi SJ et al (2020) Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma. J Hepatol 72(5):896–908PubMedCrossRef
33.
34.
Zhou J, Kryczek I, Li S, Li X, Aguilar A, Wei S, Grove S, Vatan L, Yu J, Yan Y et al (2021) The ubiquitin ligase MDM2 sustains STAT5 stability to control T cell-mediated antitumor immunity. Nat Immunol 22(4):460–470PubMedCrossRefPubMedCentral
35.
Cheng S, Castillo V, Sliva D (2019) CDC20 associated with cancer metastasis and novel mushroom–derived CDC20 inhibitors with antimetastatic activity. Int J Oncol 54(6):2250–2256PubMed
36.
Alfarsi LH, Ansari RE, Craze ML, Toss MS, Masisi B, Ellis IO, Rakha EA, Green AR (2019) CDC20 expression in oestrogen receptor positive breast cancer predicts poor prognosis and lack of response to endocrine therapy. Breast Cancer Res Treat 178(3):535–544PubMedCrossRef
37.
Mao Y, Li K, Lu L, Si-Tu J, Lu M, Gao X (2016) Overexpression of Cdc20 in clinically localized prostate cancer Relation to high Gleason score and biochemical recurrence after laparoscopic radical prostatectomy. Cancer Biomark 16(3):351–358PubMedCrossRef
38.
Choi JW, Kim Y, Lee JH, Kim YS (2013) High expression of spindle assembly checkpoint proteins CDC20 and MAD2 is associated with poor prognosis in urothelial bladder cancer. Virchows Arch 463(5):681–687PubMedCrossRef
39.
Ding ZY, Wu HR, Zhang JM, Huang GR, Ji DD (2014) Expression characteristics of CDC20 in gastric cancer and its correlation with poor prognosis. Int J Clin Exp Pathol 7(2):722–727PubMedPubMedCentral
40.
Li J, Wang Y, Wang X, Yang Q (2020) CDK1 and CDC20 overexpression in patients with colorectal cancer are associated with poor prognosis: evidence from integrated bioinformatics analysis. World J Surg Oncol 18(1):50PubMedPubMedCentralCrossRef
41.
Wang L, Yang C, Chu M, Wang ZW, Xue B (2021) Cdc20 induces the radioresistance of bladder cancer cells by targeting FoxO1 degradation. Cancer Lett 500:172–181PubMedCrossRef
42.
Gao Y, Wen P, Chen B, Hu G, Wu L, Xu A, Zhao G (2020) Downregulation of CDC20 increases radiosensitivity through Mcl-1/p-Chk1-Mediated DNA damage and apoptosis in tumor cells. Int J Mol Sci 21(18):6692PubMedCentralCrossRef
43.
Shi M, Dai WQ, Jia RR, Zhang QH, Wei J, Wang YG, Xiang SH, Liu B, Xu L (2021) APC(CDC20)-mediated degradation of PHD3 stabilizes HIF-1a and promotes tumorigenesis in hepatocellular carcinoma. Cancer Lett 496:144–155PubMedCrossRef
44.
Li J, Gao JZ, Du JL, Huang ZX, Wei LX (2014) Increased CDC20 expression is associated with development and progression of hepatocellular carcinoma. Int J Oncol 45(4):1547–1555PubMedCrossRef
45.
Luo YD, Fang L, Yu HQ, Zhang J, Lin XT, Liu XY, Wu D, Li GX, Huang D, Zhang YJ et al (2021) p53 haploinsufficiency and increased mTOR signalling define a subset of aggressive hepatocellular carcinoma. J Hepatol 74(1):96–108PubMedCrossRef
46.
Jin M, Wang J, Ji X, Cao H, Zhu J, Chen Y, Yang J, Zhao Z, Ren T, Xing J (2019) MCUR1 facilitates epithelial-mesenchymal transition and metastasis via the mitochondrial calcium dependent ROS/Nrf2/Notch pathway in hepatocellular carcinoma. J Exp Clin Cancer Res 38(1):136PubMedPubMedCentralCrossRef
47.
Ye YC, Zhao JL, Lu YT, Gao CC, Yang Y, Liang SQ, Lu YY, Wang L, Yue SQ, Dou KF et al (2019) NOTCH signaling via WNT regulates the proliferation of alternative, CCR2-independent tumor-associated macrophages in hepatocellular carcinoma. Cancer Res 79(16):4160–4172PubMedCrossRef
48.
49.
Galdiero MR, Bonavita E, Barajon I, Garlanda C, Mantovani A, Jaillon S (2013) Tumor associated macrophages and neutrophils in cancer. Immunobiology 218(11):1402–1410PubMedCrossRef
50.
Li X, Yao W, Yuan Y, Chen P, Li B, Li J, Chu R, Song H, Xie D, Jiang X et al (2017) Targeting of tumor-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Gut 66(1):157–167PubMedCrossRef
51.
Metadata
Title
Identification of CDC20 as an immune infiltration-correlated prognostic biomarker in hepatocellular carcinoma
Authors
Chen Xiong
Zhihuai Wang
Guifu Wang
Chi Zhang
Shengjie Jin
Guoqing Jiang
Dousheng Bai
Publication date
01-10-2021
Publisher
Springer US
Published in
Investigational New Drugs / Issue 5/2021
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-021-01126-1

Other articles of this Issue 5/2021

Investigational New Drugs 5/2021 Go to the issue

SHORT REPORT

Efficacy and safety of S-1 following gemcitabine with cisplatin for advanced biliary tract cancer

Short Report

Pharmacokinetics of the oral multikinase inhibitor regorafenib and its association with real‐world treatment outcomes

PRECLINICAL STUDIES

Concomitant inhibition of B7-H3 and PD-L1 expression by a novel and synthetic microRNA delivers potent antitumor activities in colorectal tumor models

Author Correction

Author Correction to: Advances in anti-BRAF therapies for lung cancer

REVIEW

The clinical efficiency of TACE combined with simultaneous computed tomography‐guided radiofrequency ablation for advanced hepatocellular carcinoma

REVIEW

The drug lag issue: a 20-year review of China
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits